---
document_datetime: 2025-12-02 06:51:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/pandemic-influenza-vaccine-h5n1-baxter-ag.html
document_name: pandemic-influenza-vaccine-h5n1-baxter-ag.html
version: success
processing_time: 0.1105252
conversion_datetime: 2025-12-28 00:29:36.504392
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Pandemic Influenza Vaccine H5N1 Baxter AG

[RSS](/en/individual-human-medicine.xml/66507)

##### Withdrawn

This medicine's authorisation has been withdrawn

pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Pandemic Influenza Vaccine H5N1 Baxter AG](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 11 September 2023 the European Commission withdrew the marketing authorisation for Pandemic Influenza Vaccine H5N1 Baxter (pandemic influenza vaccine H5N1 (whole virion, inactivated, prepared in cell culture)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Resilience Biomanufacturing Ireland Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pandemic Influenza Vaccine H5N1 Baxter was granted marketing authorisation in the EU on 16 October 2009 for prophylaxis of pandemic influenza. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

The European Public Assessment Report (EPAR) for Pandemic Influenza Vaccine H5N1 Baxter is updated to indicate that the marketing authorisation is no longer valid.

Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Summary for the public

English (EN) (190.78 KB - PDF)

**First published:** 17/12/2009

**Last updated:** 13/09/2023

[View](/en/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-253)

български (BG) (302.71 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/bg/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_bg.pdf)

español (ES) (196.16 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/es/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_es.pdf)

čeština (CS) (251.73 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/cs/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_cs.pdf)

dansk (DA) (193.38 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/da/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_da.pdf)

Deutsch (DE) (215.06 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/de/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_de.pdf)

eesti keel (ET) (186.14 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/et/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_et.pdf)

ελληνικά (EL) (312.29 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/el/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_el.pdf)

français (FR) (203.06 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/fr/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_fr.pdf)

hrvatski (HR) (237.92 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/hr/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_hr.pdf)

italiano (IT) (196.36 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/it/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_it.pdf)

latviešu valoda (LV) (250.74 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/lv/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (271.9 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/lt/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_lt.pdf)

magyar (HU) (240.63 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/hu/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_hu.pdf)

Malti (MT) (261.83 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/mt/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_mt.pdf)

Nederlands (NL) (203.3 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/nl/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_nl.pdf)

polski (PL) (254.04 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/pl/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_pl.pdf)

português (PT) (198.47 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/pt/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_pt.pdf)

română (RO) (256.87 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/ro/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_ro.pdf)

slovenčina (SK) (252.83 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sk/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_sk.pdf)

slovenščina (SL) (229.82 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sl/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_sl.pdf)

Suomi (FI) (189.11 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/fi/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_fi.pdf)

svenska (SV) (216.89 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sv/documents/overview/pandemic-influenza-vaccine-h5n1-baxter-epar-summary-public_sv.pdf)

## Product information

Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Product Information

English (EN) (2.32 MB - PDF)

**First published:** 17/12/2009

**Last updated:** 13/09/2023

[View](/en/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-743)

български (BG) (2.86 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/bg/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_bg.pdf)

español (ES) (2.31 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/es/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_es.pdf)

čeština (CS) (2.67 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/cs/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_cs.pdf)

dansk (DA) (2.3 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/da/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_da.pdf)

Deutsch (DE) (2.48 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/de/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_de.pdf)

eesti keel (ET) (2.2 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/et/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_et.pdf)

ελληνικά (EL) (2.88 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/el/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_el.pdf)

français (FR) (2.43 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/fr/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_fr.pdf)

hrvatski (HR) (2.52 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/hr/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_hr.pdf)

íslenska (IS) (2.32 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/is/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_is.pdf)

italiano (IT) (2.36 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/it/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_it.pdf)

latviešu valoda (LV) (2.55 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/lv/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.63 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/lt/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_lt.pdf)

magyar (HU) (2.53 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/hu/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_hu.pdf)

Malti (MT) (2.75 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/mt/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_mt.pdf)

Nederlands (NL) (2.32 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/nl/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_nl.pdf)

norsk (NO) (2.22 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/no/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_no.pdf)

polski (PL) (2.78 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/pl/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_pl.pdf)

português (PT) (2.27 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/pt/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_pt.pdf)

română (RO) (2.66 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/ro/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_ro.pdf)

slovenčina (SK) (2.76 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sk/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_sk.pdf)

slovenščina (SL) (2.46 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sl/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_sl.pdf)

Suomi (FI) (2.26 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/fi/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_fi.pdf)

svenska (SV) (2.23 MB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sv/documents/product-information/pandemic-influenza-vaccine-h5n1-baxter-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0032 01/02/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Pandemic Influenza Vaccine H5N1 Baxter : EPAR - All Authorised presentations

English (EN) (36.17 KB - PDF)

**First published:** 17/12/2009

**Last updated:** 13/09/2023

[View](/en/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-382)

български (BG) (77.58 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/bg/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_bg.pdf)

español (ES) (36.39 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/es/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_es.pdf)

čeština (CS) (68.82 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/cs/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (37.85 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/da/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (36.96 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/de/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.06 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/et/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.53 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/el/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_el.pdf)

français (FR) (36.19 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/fr/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (117.77 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/hr/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.21 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/is/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_is.pdf)

italiano (IT) (35.28 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/it/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.81 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/lv/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.26 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/lt/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (69.83 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/hu/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (70.99 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/mt/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (37.07 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/nl/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (37.36 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/no/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_no.pdf)

polski (PL) (70.96 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/pl/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_pl.pdf)

português (PT) (37.4 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/pt/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_pt.pdf)

română (RO) (68.56 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/ro/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.07 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sk/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.33 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sl/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.84 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/fi/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (36.12 KB - PDF)

**First published:**

17/12/2009

**Last updated:**

13/09/2023

[View](/sv/documents/all-authorised-presentations/pandemic-influenza-vaccine-h5n1-baxter-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Pandemic Influenza Vaccine H5N1 Baxter AG Active substance influenza vaccine (whole virion, inactivated) containing antigen of: A/Vietnam/1203/2004 (H5N1) International non-proprietary name (INN) or common name pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture) Therapeutic area (MeSH)

- Influenza, Human
- Immunization
- Disease Outbreaks

Anatomical therapeutic chemical (ATC) code J07BB01

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.

## Authorisation details

EMA product number EMEA/H/C/001200

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Resilience Biomanufacturing Ireland Limited

Resilience Biomanufacturing Ireland Limited

Opinion adopted 23/08/2009 Marketing authorisation issued 16/10/2009 Withdrawal of marketing authorisation 11/09/2023 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (829.88 KB - PDF)

**First published:** 14/06/2012

**Last updated:** 13/09/2023

[View](/en/documents/procedural-steps-after/pandemic-influenza-vaccine-h5n1-baxter-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Pandemic Influenza Vaccine H5N1-H-C-1200-P46-0020 : EPAR - Assessment Report

Adopted

Reference Number: EMA/770863/2014

English (EN) (1.24 MB - PDF)

**First published:** 10/12/2014

**Last updated:** 13/09/2023

[View](/en/documents/variation-report/pandemic-influenza-vaccine-h5n1-h-c-1200-p46-0020-epar-assessment-report_en.pdf)

Pandemic Influenza Vaccine H5N1 Baxter-H-C-1200-II-0015 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/65558/2014

English (EN) (1.91 MB - PDF)

**First published:** 06/02/2014

**Last updated:** 13/09/2023

[View](/en/documents/variation-report/pandemic-influenza-vaccine-h5n1-baxter-h-c-1200-ii-0015-epar-assessment-report-variation_en.pdf)

Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/65572/2014

English (EN) (113.32 KB - PDF)

**First published:** 06/02/2014

**Last updated:** 13/09/2023

[View](/en/documents/pip-compliance/pandemic-influenza-vaccine-h5n1-baxter-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

CHMP post-authorisation summary of positive opinion for Pandemic influenza vaccine H5N1 Baxter

Adopted

Reference Number: EMA/CHMP/648055/2013

English (EN) (104.85 KB - PDF)

**First published:** 25/10/2013

**Last updated:** 13/09/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-pandemic-influenza-vaccine-h5n1-baxter_en.pdf)

## Initial marketing authorisation documents

Pandemic Influenza Vaccine H5N1 Baxter : EPAR - Public assessment report

English (EN) (114.87 KB - PDF)

**First published:** 17/12/2009

**Last updated:** 13/09/2023

[View](/en/documents/assessment-report/pandemic-influenza-vaccine-h5n1-baxter-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use, summary of positive opinion for Pandemic Influenza Vaccine H5N1 Baxter

Reference Number: EMEA/CHMP/446619/2009

English (EN) (62.79 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 13/09/2023

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-pandemic-influenza-vaccine-h5n1-baxter_en.pdf)

#### News on Pandemic Influenza Vaccine H5N1 Baxter AG

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 October 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-october-2013) 25/10/2013

**This page was last updated on** 13/09/2023

## Share this page

[Back to top](#main-content)